Please login to the form below
Aeterna Zentaris looks to Boehringer for science head
Richard Sachse joins Canadian firm as chief scientific officer
Aeterna Zentaris has appointed Boehringer Ingelheim's Dr Richard Sachse as senior VP and chief scientific officer.
Dr Sachse was most recently head of global translational medicine at Germany-based Boehringer following several roles at major pharma companies in Europe, including Bayer, Schwarz Pharma and UCB.
He will now make the move to Canada to take on his role at Aeterna Zentaris, which specialises in oncology and endocrinology.
The company's president and CEO David Dodd outline Dr Sachse's new role: “As CSO, he will be responsible for all areas of our global research and development activities, while also serving on the corporate operating committee.”
Dr Sachse said he was “delighted” by the opportunity his new position offered him.
He said: “I believe that the combination of Aeterna Zentaris' highly qualified and motivated personnel, together with its strong scientific platform, holds much promise for the future success of our projects."
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
